Scancell Holdings Plc Technology acquired from University of Nottingham
April 18 2018 - 1:01AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
18 April 2018
18 April 2018
Scancell to acquire novel immunotherapy platform technology from
the University of Nottingham
Antibodies to tumour-associated glycans have potential as a new
class of cancer immunotherapy
Complementary to Company's other platforms, ImmunoBody(R) and
Moditope(R)
Scancell Holdings plc, ('Scancell' or the 'Company'), the
developer of novel immunotherapies for the treatment of cancer,
announces that it has entered into an agreement with the University
of Nottingham to acquire a number of novel monoclonal antibodies to
tumour-associated glycans ("Assigned Antibodies"). Alongside this,
Scancell has also acquired a proprietary technology to enable the
modification of the constant region (F(C) ) of a human antibody to
allow direct tumour killing. Together these offer a complementary
platform to Scancell's existing cancer immunotherapy platforms,
ImmunoBody(R) and Moditope(R).
Advances in understanding the pattern of sugars (glycans) that
adorn cells have highlighted important differences between those on
tumour cells versus their normal counterparts. This altered sugar
signature of tumour cells is intricately linked to the majority of
cancer cell biology hallmarks. Antibodies that target such tumour
glycan signatures, when coupled to a novel approach to invoke an
immune response on binding, provide an attractive strategy for
immunotherapy and forms the basis of the platform technology
developed by Prof. Lindy Durrant and her team at the Nottingham
University Therapeutic Antibody Centre (NUTAC).(1)
Scancell will be responsible for the management, prosecution and
maintenance of any patent applications assigned from the University
of Nottingham to Scancell, as well as for the filing of new patent
applications for the Assigned Antibodies. Under the terms of the
agreement, the University of Nottingham is eligible to receive
royalties on future licence revenue or net sales arising from the
Assigned Antibodies.
Dr Cliff Holloway, CEO of Scancell, commented: "Prof. Durrant
and the team at NUTAC have developed a versatile method to generate
high-affinity monoclonal antibodies against cancer cell glycans
that, when coupled to a novel method of activating the immune
system, have potential as a new class of cancer immunotherapy. We
believe this platform complements our existing ImmunoBody(R) and
Moditope(R) platforms, significantly broadening the strength and
potential of Scancell's immunotherapy pipeline."
Dr Susan Huxtable, Director of Technology Transfer for the
University of Nottingham, commented: "We have great confidence in
Scancell's ability to further develop University intellectual
property. The mutually-beneficial relationship between Scancell and
the University is an excellent example of University technology
transfer in action."
(1.) Oncoimmunology. 2016; 5(1): e1061177. Published online 2015
Jul 15. doi: 10.1080/2162402X.2015.1061177
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon & Co
(Nominated Adviser and Corporate
broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
FTI Consulting
Mo Noonan/Simon Conway +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents. It stimulates the production of
killer CD4 T cells which overcome the immune suppression induced by
tumours, allowing activated T cells to seek out and kill tumour
cells that would otherwise be hidden from the immune system.
Moditope(R) alone, or in combination with other agents, has the
potential to treat of a wide variety of cancers.
-- Modi-1 is being developed for the treatment of triple
negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFKODPFBKDDQD
(END) Dow Jones Newswires
April 18, 2018 02:01 ET (06:01 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024